Entities / Person
Vinay Prasad.
US hematologist–oncologist
- Reports this week
- 0
- Active events
- 0
- Connections
- 8
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
uniQure N.V. is seeking FDA approval for a gene therapy targeting Huntington's disease amid leadership changes impacting the review process.Some support2 reports
-
New leadership within the FDA emphasized the importance of randomized controlled trials as of July 22, 2025.Some support1 report
-
Vinay Prasad returned to lead CBER at the FDA on August 12, 2025.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Vinay Prasad this week
News at the entities that move Vinay Prasad most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Vinay Prasad
-
Moderna OperationalAnalyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Moves Vinay Prasad
Connections
The 3 strongest of 8, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Vinay Prasad holds a high-ranking leadership role within the FDA, specifically overseeing the critical CBER division and gene therapy review processes.
-
Moderna Operational
Vinay Prasad leverages his expertise and professional background to influence Moderna's operational standards and regulatory review processes.
-
Sarepta Therapeutics Shared context
Vinay Prasad's regulatory actions and critiques influence the drug approval environment in which Sarepta operates.
History
Events by the month they beganJune 2026
3 events- uniQure N.V. is seeking FDA approval for a gene therapy targeting Huntington's disease amid leadership changes impacting the review process.
- New leadership within the FDA emphasized the importance of randomized controlled trials as of July 22, 2025.
- Vinay Prasad returned to lead CBER at the FDA on August 12, 2025.